These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 32774695)

  • 1. Immune checkpoint targeting TIGIT in hepatocellular carcinoma.
    Zheng Q; Xu J; Gu X; Wu F; Deng J; Cai X; Wang G; Li G; Chen Z
    Am J Transl Res; 2020; 12(7):3212-3224. PubMed ID: 32774695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
    Yeo J; Ko M; Lee DH; Park Y; Jin HS
    Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33670993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.
    Jin S; Zhang Y; Zhou F; Chen X; Sheng J; Zhang J
    Front Oncol; 2022; 12():1091782. PubMed ID: 36605439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
    Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
    Transl Oncol; 2024 Jul; 45():101961. PubMed ID: 38631259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
    Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
    Front Immunol; 2021; 12():699895. PubMed ID: 34367161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the immune checkpoint receptor TIGIT in seminoma.
    Hinsch A; Blessin NC; Simon R; Kluth M; Fischer K; Hube-Magg C; Li W; Makrypidi-Fraune G; Wellge B; Mandelkow T; Debatin NF; Höflmayer D; Lennartz M; Sauter G; Izbicki JR; Minner S; Büscheck F; Uhlig R; Dum D; Krech T; Luebke AM; Wittmer C; Jacobsen F; Burandt E; Steurer S; Wilczak W
    Oncol Lett; 2019 Aug; 18(2):1497-1502. PubMed ID: 31423216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIGIT as an emerging immune checkpoint.
    Harjunpää H; Guillerey C
    Clin Exp Immunol; 2020 May; 200(2):108-119. PubMed ID: 31828774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
    Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TIGIT therapies for solid tumors: a systematic review.
    Rousseau A; Parisi C; Barlesi F
    ESMO Open; 2023 Apr; 8(2):101184. PubMed ID: 36933320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update in TIGIT Immune-Checkpoint Role in Cancer.
    Annese T; Tamma R; Ribatti D
    Front Oncol; 2022; 12():871085. PubMed ID: 35656508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
    Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
    Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
    Shirasuna K; Koelsch G; Seidel-Dugan C; Salmeron A; Steiner P; Winston WM; Brodkin HR; Nirschl CJ; Abbott S; Kinugasa F; Sugahara S; Ohori M; Takeuchi M; Hicklin DJ; Yoshida T
    Cancer Treat Res Commun; 2021; 28():100433. PubMed ID: 34273876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT in cancer immunotherapy.
    Chauvin JM; Zarour HM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.
    Wang D; Gu Y; Yan X; Huo C; Wang G; Zhao Y; Teng M; Li Y
    Front Oncol; 2022; 12():844260. PubMed ID: 35433470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.
    Xiao Y; Chen P; Luo C; Xu Z; Li X; Liu L; Zhao L
    Cancer Treat Res Commun; 2021; 29():100467. PubMed ID: 34598062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8
    Shaw G; Cavalcante L; Giles FJ; Taylor A
    J Hematol Oncol; 2022 Sep; 15(1):134. PubMed ID: 36104795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].
    Wu J; Ren D; Bi H; Yi B; Wang H
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):819-827. PubMed ID: 36419396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.